Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2021-01-25 Earnings Release
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
Eurobio Scientific: EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%)
Earnings Release Classification · 99% confidence The document explicitly states it presents the "consolidated annual turnover as of December 31, 2020." It includes a summary table comparing 2020 turnover to 2019, notes that the figures are '*unaudited*', and discusses performance over the full financial year. This content strongly indicates a preliminary release of annual financial performance data, which aligns best with an Earnings Release (ER) or potentially an Annual Report (10-K) if it were the full filing. However, the presence of a disclaimer and the announcement of the '2020 annual results' release date (April 14, 2021) suggests this document is the initial announcement summarizing the annual performance, rather than the comprehensive 10-K filing itself. Given the focus on turnover figures and the timing relative to the official results release, 'ER' (Earnings Release) is the most appropriate classification for this preliminary annual summary. FY 2020
2021-01-25 English
Eurobio Scientific expands its range of COVID-19 tests with an antigenic rapid test
Earnings Release Classification · 95% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a business development: the expansion of Eurobio Scientific's COVID-19 test range, including a new antigenic rapid test, and confirms their PCR tests detect new variants. It also mentions an upcoming financial meeting date ("2020 Sales: January 25, 2021"). This structure—a brief announcement of news, product updates, and forward-looking statements, often released outside of mandatory SEC filing cycles—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing operational and product news, and not the full financial report (10-K or IR), Earnings Release (ER) is the most appropriate fit, as these often accompany or precede formal earnings reports, even if the primary focus here is product news related to the pandemic context. It is not a 10-K (too short, not comprehensive annual report), not an AR (not a standalone audit), not an IP (it's a press release, not a detailed investor presentation), and not an RPA (it contains substantive news, not just an announcement of a report). Given the context of announcing business updates and referencing an upcoming sales announcement, ER is the best fit among the specific options. FY 2021
2021-01-18 English
Eurobio Scientific complète sa gamme de tests COVID-19 avec un test antigénique rapide
Earnings Release Classification · 95% confidence The document is a press release dated January 18, 2021, announcing that Eurobio Scientific has completed its COVID-19 test range with a new rapid antigen test. It details the features of the new test, mentions partnerships, discusses PCR test performance, and concludes with a section titled "Prochain rendez-vous financier" (Next financial appointment) listing the date for the 2020 results release (January 25, 2021). This structure—a news announcement about a product/business update, often including forward-looking statements and contact information, but not being a full statutory report (like 10-K or IR) or a transcript—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is announcing business developments and providing a date for the upcoming financial results release, it functions primarily as an Earnings Release, even if it's not the full results themselves. It is a direct announcement of operational news rather than a formal regulatory filing fallback (RNS) or a report itself (10-K, IR). The mention of the upcoming financial results date strongly suggests this is an ER or closely related communication. FY 2021
2021-01-18 French
EUROBIO SCIENTIFIC : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE PAR EUROBIO SCIENTIFIC AVEC LOUIS CAPITAL MARKETS
Regulatory Filings Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE PAR EUROBIO SCIENTIFIC AVEC LOUIS CAPITAL MARKETS" (Semi-annual balance sheet of the liquidity contract entered into by Eurobio Scientific with Louis Capital Markets). It details the status of a liquidity contract, including the number of shares and cash balance as of the reporting date (January 15, 2021, reporting on the period up to the end of 2020), and provides transaction details (purchases and sales) during the first half of 2020. This type of regular disclosure regarding market making or liquidity agreements is a specific type of regulatory or ongoing disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). Since it is a specific, recurring report detailing the status of a financial arrangement (liquidity contract), it fits best under the general category of ongoing regulatory disclosures or specific financial updates. Given the options, it is a specific financial disclosure related to market operations. It is not a transaction in own shares (POS) as it relates to a third-party market maker's actions under contract, nor is it a capital change (SHA). It is a periodic report on a specific financial arrangement. Since there is no explicit 'Liquidity Contract Report' code, and it is a detailed, periodic report, it is closest to an Interim Report (IR) if it were a comprehensive financial statement, but it is highly specialized. However, based on the nature of periodic disclosures that don't fit the main categories, and given that it is a detailed report (15k+ characters) rather than a mere announcement of a report, it is most appropriately classified as a specialized financial disclosure. In the absence of a better fit, and considering it reports on financial activity over a period, it leans towards a specialized financial report. If we must choose from the provided list, and recognizing it is a periodic report detailing financial activity (even if contractual), it is a specific type of financial update. Since it is a detailed report and not just an announcement, we avoid RPA/RNS. It is a report on the status of a financial instrument/contract. This type of disclosure often falls under general regulatory filings (RNS) or specialized financial reports. Given the detailed nature and specific financial focus, and lack of a better fit, RNS (Regulatory Filings - fallback for miscellaneous filings) is the safest classification for a non-standard, periodic disclosure, although it is highly specific. Let's re-evaluate: It is a 'Bilan Semestriel' (Semi-annual Balance Sheet) for a liquidity contract. This is a mandatory disclosure in many jurisdictions for companies with such agreements. It is a periodic financial disclosure. Since 'IR' (Interim Report) is defined as a comprehensive financial report for a shorter period, and this is highly specific, RNS is the most appropriate fallback for a specific, non-standard regulatory disclosure. I will assign RNS as the best fit among the provided codes for a specialized, periodic regulatory disclosure not covered elsewhere.
2021-01-15 French
EUROBIO SCIENTIFIC CONFIRME SON ELIGIBILITE AU DISPOSITIF PEA-PME
Regulatory Filings Classification · 95% confidence The document is a short press release dated January 8, 2021, announcing that Eurobio Scientific confirms its eligibility for the PEA-PME scheme (a French investment vehicle). It also provides a date for the next financial update ('Chiffre 2020 : 25 janvier 2021') and includes standard company background, contact information, and a forward-looking statement disclaimer. This format—a brief announcement of a specific corporate event or status update, often including upcoming dates—is characteristic of a general regulatory announcement or press release that doesn't fit the specific categories like Earnings Release (ER) or Capital Update (CAP). Since it is a general corporate update that doesn't fit the more specific categories (like DIV, DIRS, ER, 10-K, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length is short (2995 chars), suggesting it is an announcement rather than a full report.
2021-01-08 French
Eurobio Scientific : Rapport Financier Semestriel 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Interim Financial Report) for the period ending June 30, 2020. It contains comprehensive financial statements, including the consolidated balance sheet, income statement, cash flow statement, and notes to the financial statements, as well as a management discussion and analysis of the results. It is not a mere announcement or certification, but the full interim report itself. H1 2020
2020-10-16 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.